Is LSA (Morning Glory) legal in Finland?

Legal status

Not a narcotic in Finland, and not named anywhere as a substance. Lysergic acid amide is not named in any annex of valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista 543/2008, is not named in the annex to valtioneuvoston asetus 1130/2014, and is not named in annex 1 or annex 1 A of the medicines list 230/2025, as those annexes stand after 651/2026, 1119/2025 and 650/2026. What the medicines list does name, in annex 2 among the rohdokset, are the plants that carry it, and the row for the Hawaiian baby woodrose opens its Latin column «Argyreia nervosa». Annex 2 puts the Latin name first, and this row gives its Finnish name as Havaijilainen puuruusu and its English name as Hawaiian baby woodrose. Rivea corymbosa and several Ipomoea species have their own rows in the same annex. Section 3 of that decision supervises the annex 2 rohdokset as medicines when they are used in the way section 3 subsection 1 of lääkelaki 395/1987 describes. The live Finland cell's own unresolved reasoning is kept. It recorded that the express wording «Lysergihapon amidi» was located in the superseded 1993 decision 1709/1993 with no current carry forward identified, that lysergic acid is a category 1 precursor under Regulation (EC) No 273/2004 annex I whose salts clause does not establish the distinct amide, and that failed Finlex positive controls prevented reliance on a zero search result. Those three points are carried forward and were not re-derived here. The live Finland cell also quoted «(+)-Lysergidi (LSD, LSD-25)», «Lysergihappo» and «Ipomoea sp.» and those three are kept.

Consequences if caught

Capital exposure: none. No penalty is asserted for this entry as a class, because the classification itself is unresolved. Criminal Code chapter 44 section 5 carries the medicines offence. It sets a fine or up to one year for manufacturing, importing, storing, keeping for sale or supplying medicines contrary to the Medicines Act or the European Union medicines regulations, unless a heavier penalty is provided elsewhere. Chapter 50 of the Criminal Code (39/1889) carries the narcotics offences. Section 1 sets a fine or up to two years for a huumausainerikos covering manufacture, cultivation, import, export, transport, sale, supply, distribution and possession. Section 2 sets one to ten years for a törkeä huumausainerikos where the object is a very dangerous narcotic or a large quantity, or substantial gain is sought, or the act is part of an organised group, or serious danger to life or health is caused to several people, or the drug is spread to minors. Section 2 a sets a fine or up to six months for a huumausaineen käyttörikos, unlawful use or possession of a small quantity for own use. Section 3 sets a fine or up to two years for preparation and section 4 the same for promotion, while section 4 a sets four months to six years for aggravated promotion. Section 7 allows the charge or the sentence to be waived where the quantity, the circumstances and the use situation make the act minor as a whole, or where the suspect has entered approved treatment. The live Finland cell recorded the same three provisions and asserted no custodial term at all, and every provision it named is carried here: Criminal Code (39/1889) chapter 50, the substantive prohibitions in Narcotics Act 373/2008 section 5 with the lawful exceptions in section 3, and the consumer market conduct offence in Criminal Code chapter 44 section 5 a. The bands stated above are new to this pass and were read off the Criminal Code itself, not carried from that cell. Whether the offence reaches this row at all is exactly what was not established here. This row in particular. It is not named in either decree and that is a measured absence, not an assumption. The Finnish forms put to both texts for this row were «Lysergihapon amidi», «Lysergiamidi», «Argyreia», «Ipomoea», «Rivea», «LSA». Against the consolidated 543/2008, whose annexes carry 196 entries in Liite I, 192 in Liite II, 11 in Liite III, 70 in Liite IV and 1 in Liite V, and against the annex to 1130/2014 as substituted by 650/2026, no form returned an entry of its own. No near miss came back either: not one entry in either annex contains any of those forms as a substring, so there is no longer name to be mistaken for this one. The bands stated above are the narcotics bands and they are reproduced because the live cell named chapter 50. They describe the lane this row would fall into if it were listed, and on the text read here it is not.

If prescribed or medical

This row's whole answer is the prescription route, and whether an authorised product exists in a given form is a product by product question that this cell does not settle. Sections 3 and 6 of lääkelaki 395/1987 are the provisions the live Finland cell named for this route and they are kept. Where a substance is a medicinal ingredient rather than a listed narcotic, it is handled through the Medicines Act 395/1987, in particular the conduct and import rules in section 3 and the medicinal substances list, and its status turns on individual product classification. This row in particular. The list that does name this row is the medicines list, Finnish Medicines Agency decision 230/2025. Its Liite 2 carries the row at printed line 4116 of the annex text Finlex serves, and the printed row reads «Argyreia nervosa Havaijilainen puuruusu, Elefantvinda Hawaiian baby woodrose,». In the printed order of that annex the line above it reads (Carex arenaria) and the line below it reads ruusunorsukierto Elephant creeper. A second row for this substance sits in Liite 2 of the same list at printed line 4535, reading «Ipomoea sp. Elämänlangat Ipomoea Ipomoea».

Documentation

Section 24 of huumausainelaki 373/2008 is written for convention listed narcotics and does not describe this row, so the ordinary medicines rules are what apply. Carry any prescribed medicine in its dispensed packaging with the prescription. Finland's personal import rules for medicines sit in the Medicines Act 395/1987 and were not read for this cell, so no traveller allowance is stated here. This row in particular. The search behind the absence stated for this row was run in Finnish and the forms were «Lysergihapon amidi», «Lysergiamidi», «Argyreia», «Ipomoea», «Rivea», «LSA». Section 24 of huumausainelaki 373/2008, the provision that would otherwise carry a traveller's own medicine past the Act's import and export rules, reaches only products «joita matkustaja käyttää henkilökohtaiseen lääkitykseensä» that contain a substance in one of the convention lists, and this row is in none of them. The list that does name this row is the medicines list, Finnish Medicines Agency decision 230/2025. Its Liite 2 carries the row at printed line 4116 of the annex text Finlex serves, and the printed row reads «Argyreia nervosa Havaijilainen puuruusu, Elefantvinda Hawaiian baby woodrose,». In the printed order of that annex the line above it reads (Carex arenaria) and the line below it reads ruusunorsukierto Elephant creeper. A second row for this substance sits in Liite 2 of the same list at printed line 4535, reading «Ipomoea sp. Elämänlangat Ipomoea Ipomoea». Provenance for this row. The consolidated 543/2008 read here is the Finlex text carrying amendments up to 25.6.2026/651, the version Finlex identifies as data.finlex.fi/eli/sd/2008/543/ajantasa/2026-06-26/fin, in force from 10 July 2026, read on 21 September 2026; the consolidated 1130/2014 read here is the Finlex text whose annex was substituted by 650/2026 with effect from 10 July 2026, read on 21 September 2026; and where the medicines list is cited it is the Finnish annex text to decision 230/2025 served by Finlex, read on 21 September 2026.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Finland’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.